Table 1.
Participant Demographics and Clinical Characteristics.
| No-FES (n=13) | FES (n=10) | Test Statistic | |
|---|---|---|---|
| Female, % | 62 | 70 | Χ21=.18, p=.67 |
| Age (y) (SD) | 41.2 (14.2) | 54.0 (10.3) | T21=−2.51, p=.03 |
| Race | |||
| White, % | 92.3 | 90 | Χ21=.04, p=.85 |
| Black, % | 7.7 | 10 | |
| Chronicity (y) (SD) | 4.3 (2.5) | 9.7 (8.6) | T10=−1.92, p=.08 |
| Diagnosis | |||
| Stroke, % | 61 | 100 | |
| Traumatic Brain Injury, % | 39 | 0 | Χ21=1.89, p=.16 |
| Location of insult | |||
| Cortical, % | 92.3 | 100 | |
| Subcortical, % | 7.7 | 0 | Χ21=.80, p=.37 |
| OnabotulinumtoxinA dose, | |||
| units, (SD) | 251.8 (123.5) | 328.6 (90.6) | T21=−1.65,p = .11 |
| Baseline Measures | |||
| MAL-O, (SD) | 1.11 (.87) | .96 (.84) | T21=.43, p=.68 |
| MAS-SR, (SD) | 1.55 (.96) | 1.17 (.74) | T21=1.02,p=.32 |
| ARAT, (SD) | 25.8 (15.5) | 19.5 (13.9) | T21=1.00, p=.33 |
| MAS-Wrist, median (IQR) | 3 (2,3) | 3 (3,4) | Z=−.57,p=.61 |
| MAS-Fingers, median (IQR) | 3(2,3) | 3(3,3) | Z=−.95,p=.41 |
NOTE. Data represent mean and SD except where indicated. No-FES: subjects who received OnabotulinumtoxinA injections and task practice therapy. FES: subjects who received Cylic FES in addition to OnabotulinumtoxinA injections and task practice therapy.
Abbreviations: IQR, interquartitle range; MAS, Modified Ashworth scales; MAL-O, Motor Activity Log Observation; MAL-SR, Motor Activity Log Self-Report.